文献速递甲状腺疾病

成人RTHα患者左甲状腺素治疗的安全性、疗效及代谢组学变化

Thyroxine Treatment of Adult RTHα Patients: Safety, Efficacy, and Metabolomic Changes.
PubMed 文献 · Thyroid · 2026-06-11

本研究在4例RTHα(Ala263Val)成人患者中开展开放标签试点研究,给予左甲状腺素(L-T4)1.75 µg/kg治疗并随访三年,评估生活质量、生化指标、骨密度及代谢组学。L-T4使FT4、FT3、rT3升至超生理浓度并抑制TSH,未见不良事件,患者生活质量改善,骨密度似无改变,部分脂质降低。

要点

  • L-T4治疗可改善RTHα成人患者生活质量且安全性良好。
  • 治疗使甲状腺激素升至超生理水平并抑制TSH,需监测心率及骨代谢。
  • 部分患者L-T4联合L-T3时出现短阵非持续性室性心动过速。

核心结论

  • 成人RTHα患者接受L-T4治疗安全,且依从患者生活质量改善。

研究设计与样本

  • 开放标签试点研究,纳入4例RTHα(Ala263Val)成人患者,L-T4剂量1.75 µg/kg,随访三年,并尝试部分以L-T3替代L-T4。

主要发现

  • L-T4使FT4、FT3、rT3升至超生理浓度并抑制TSH,无不良事件。
  • 心率、骨标志物及性激素结合球蛋白一过性升高,骨密度似无改变。
  • 多类脂质降低,患者生活质量改善。
  • 1例患者在L-T3联合L-T4治疗时出现短阵非持续性室性心动过速。

临床怎么用

  • 对成人RTHα患者可考虑L-T4治疗以改善生活质量,但需监测甲状腺激素水平、心率及骨代谢。
  • L-T4联合L-T3时需警惕室性心律失常风险。

局限性

  • 样本量小(4例),为开放标签试点研究,结果需更大规模研究验证。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Resistance to thyroid hormone alpha (RTHα) is a rare genetic disorder with symptoms of hypothyroidism, but normal or close-to-normal thyroid function tests. Treatment with levothyroxine (L-T4) may be beneficial. This study investigated the efficacy, safety and biochemical changes of high-dose L-T4 and liothyronine (L-T3) treatment. METHODS: Four RTHα (Ala263Val) patients were treated with L-T4 (1.75 µg/kg) in a pilot open-label study and monitored for three years. Quality of life (QoL) was assessed using ThyPro. Analysis of auxiological- and biochemical-parameters, bone mineral density (BMD) and exploratory metabolomics was performed. A partial replacement of L-T4 with L-T3 was attempted. RESULTS: Treatment with L-T4 increased FT4, FT3, and rT3 to supraphysiological concentrations (relative to reference intervals) and suppressed thyroid-stimulating hormone with no adverse effects. Heart rate, bone markers, and sex hormone-binding globulin transiently increased. Several classes of lipids were reduced. BMD appeared unaltered. Patients reported improved QoL. One patient presented a short non-sustained ventricular tachycardia on L-T3 + L-T4. CONCLUSIONS: L-T4 treatment of adult RTHα patients was safe and improved QoL in adherent patients.

来源:Thyroid,查看原文。版权归原作者所有。

引用

  1. Westbye AB, Dahll LK, Bredahl MK, et al. Thyroxine Treatment of Adult RTHα Patients: Safety, Efficacy, and Metabolomic Changes. Thyroid. 2026. PMID: 42273878. doi:10.1177/10507256261460201

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。